Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 24;6(2):ooad042. doi: 10.1093/jamiaopen/ooad042

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of the American Medical Informatics Association.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 6. — Ratios of assigned male at birth (AMAB) compared to assigned female at birth (AFAB) for gender-expansive identity and use of gender-affirming therapy in different age categories. (A) Breakdown of transgender male patients compared to transgender female as a percentage of total patients within specific age distributions. (B) Breakdown of AMAB nonbinary patients compared to AFAB nonbinary patients as a percentage of total patients within specific age distributions. (C) Breakdown of all gender-expansive patients (including transgender, nonbinary and other gender-expansive identities) into those who are AMAB compared to AFAB as a percentage of total patients within specific age distributions. (D) Ratio of AMAB to AFAB for all gender-expansive patients within specific age distributions. The dashed line represents a ratio of 1.0. (E) Breakdown of gender-affirming medications within specific age distributions. (F) Ratio of AMAB to AFAB for patients who were receiving gender-affirming medications within specific age distributions. Total patient population is 123 441 (<12 years, N = 6547; 12–17 years, N = 6177; 18–29 years, N = 17 123; 30–39 years, N = 15 452; 40–49 years, N = 14 963; 50–59 years, N = 18 508; 60–69 years, N = 22 692; 12–17 years, N = 15 515; 80 years or older, N = 6464).